# Standards for external control arms built from federated real-world data

Source: https://onco.cc/ideas/idea-data-external-control-arm-standard/  
OnCo record `idea-data-external-control-arm-standard` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

When a trial has no comparison group, the comparison is sometimes built from old patient records. Set rules for how that is done so the answer is not rigged.

## Summary

External control arms from real-world or historical trial data are increasingly used in rare cancers and single-arm approvals, with inconsistent methods. The proposal defines standards: pre-specification before trial unblinding, construction from federated data with documented eligibility mapping, minimum covariate set, quantitative bias analysis and tipping-point sensitivity analyses, plus public deposition of the control cohort definition. Regulatory guidance (FDA 2023 draft on externally controlled trials) is the starting point.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Standardised external controls will reduce the discrepancy between single-arm effect estimates and subsequent randomised confirmation by half.
- Rationale: Several single-arm approvals with historical controls were later contradicted by randomised trials; the failures trace to unmeasured confounding and cherry-picked comparators, both addressable by pre-specification and bias analysis.
- Proposed test: Reconstruct external controls under the standard for ten single-arm approvals that later had randomised confirmation; compare the standardised estimate with the randomised result.
- Maturity: early-clinical
- Actor: regulator

## Sources

- Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019): https://doi.org/10.1001/jamainternmed.2019.0462

## Connected records

- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/)
- terms: [Basket, umbrella, and platform trials](https://onco.cc/terms/basket-umbrella-platform/), [Real-world evidence](https://onco.cc/terms/real-world-evidence/)
- bottlenecks: [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/), [Weak real-world evidence and registries](https://onco.cc/bottlenecks/b-real-world-evidence/)
- key papers: [Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval](https://onco.cc/key-papers/paper-gyawali-jama-intern-med/)

---
JSON: https://onco.cc/api/v1/entities/idea-data-external-control-arm-standard.json